Stock Rating Downgrade
The Value Trend Rating for Fate Therapeutics Inc (NASDAQ: FATE) weakened recently from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
Fate Therapeutics Inc (NASDAQ: FATE) stock enjoyed a large increase of 2.2% on 1/12/24. The stock closed at $4.55. Moreover, unusually high trading volume at 163% of normal accompanied the advance. The stock has been extremely weak relative to the market over the last nine months but has risen 18.5% during the last week.
Current PriceTarget Research Rating
FATE’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to continue to be a modest Value Eraser.
Fate Therapeutics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Fate Therapeutics has a slightly positive Appreciation Score of 64 but a very low Power Rating of 14, triggering the Negative Value Trend Rating.
Be the first to comment